GlassScriptPhysician profile
Robert W Schuyler
NPI 1982601902
$1,937.56
in general payments reported to CMS, 2019-2025
22 companies · $423 in 2025
The $423 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $142 · 2021: $151 · 2022: $40.75 · 2023: $274 · 2024: $720 · 2025: $423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,417.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $272.30 | 2023-2025 | Orgovyx, Gemtesa |
| Axonics, INC. | $268.46 | 2024 | Axonics |
| Boston Scientific Corporation | $206.55 | 2022-2025 | Axonics, Lumenis Pulse 120h |
| Pfizer INC. | $196.79 | 2019-2025 | |
| Astellas Pharma US INC | $174.09 | 2019-2023 | Veozah |
| Coloplast Corp | $147.83 | 2024-2025 | |
| Janssen Biotech, INC. | $121.45 | 2019-2024 | Erleada, Akeega |
| Endo Pharmaceuticals INC. | $104.87 | 2020-2024 | Aveed, Xiaflex |
| Procept Biorobotics Corporation | $72.49 | 2024-2025 | Aquabeam System |
| Abbvie INC. | $56.64 | 2023-2024 | Botox |
| Endo USA, INC. | $50.72 | 2025 | Aveed, Xiaflex |
| Olympus America INC. | $42.44 | 2019-2023 | Soltive |
| Laborie Medical Technologies Corp. | $31.03 | 2024 | Urgent PC Neuromodulation System |
| Amgen INC. | $28.63 | 2019-2021 | |
| Urogen Pharma, INC. | $27.44 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $24.33 | 2023 | Nocdurna, Xyosted, Tlando |
| Allergan, INC. | $23.16 | 2019-2021 | |
| Neotract INC. | $22.36 | 2019 | |
| Photocure INC | $16.83 | 2020 | |
| Glaxosmithkline, LLC. | $16.81 | 2025 | Bexsero |
| C. R. Bard, INC. & Subsidiaries | $16.61 | 2019 | |
| Rochester Medical Corporation | $15.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Schuyler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.